Suppr超能文献

微创细胞减灭术联合 HIPEC 治疗上皮性卵巢癌:系统评价。

Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.

机构信息

Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.

Unit of Gynecologic Oncology, Department of Woman, Child and Public Health, A. Gemelli, IRCCS, University Hospital Foundation, 00198 Rome, Italy.

出版信息

Medicina (Kaunas). 2023 Feb 21;59(3):421. doi: 10.3390/medicina59030421.

Abstract

The Gold-Standard treatment for Advanced Epithelial Ovarian Cancer remains cytoreductive surgery followed by systemic chemotherapy. Surgery can be performed either by an open or minimally invasive approach (MIS), although the former remains the most widely used approach. Recently, Van Driel et al. proved that adding 100 mg/m of Cisplatin in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Interval Debulking Surgery (IDS) gives a disease-free survival (DFS) advantage. Similarly, Gueli-Alletti et al. demonstrated how the MIS approach is feasible and safe in IDS. Moreover, Petrillo et al. reported pharmacokinetic profiles with a higher chemotherapy concentration in patients undergoing HIPEC after MIS compared with the open approach. Therefore, the following review investigates the oncological and clinical safety consequences of the association between MIS and HIPEC. Following the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, we systematically searched the PubMed and Scopus databases in April 2022. Studies containing data about oncological and safety outcomes were included. We registered the Review to the PROSPERO site for meta-analysis with protocol number CRD42022329503. Five studies fulfilled inclusion criteria. 42 patients were included in the review from three different Gynecological Oncological referral centers. The systematic review highlighted a Recurrence Rate ranging between 0 and 100%, with a 3-year Platinum-Free Survival between 10 and 70%. The most common HIPEC drug was Cisplatin, used at concentrations between 75 and 100 mg/m and at an average temperature of 42 °C, for 60 to 90 min. Only 1 Acute Kidney Insufficiency has been reported. The scarcity of clinical trials focusing on a direct comparison between MIS and the open approach followed by HIPEC in EOC treatment does not make it possible to identify an oncological advantage between these two techniques. However, the safety profiles shown are highly reassuring.

摘要

高级上皮性卵巢癌的金标准治疗仍然是细胞减灭术加全身化疗。手术可以通过开放或微创(MIS)方法进行,尽管前者仍然是最广泛使用的方法。最近,Van Driel 等人证明,在间隔肿瘤细胞减灭术(IDS)中添加 100mg/m 顺铂的腹腔内热化疗(HIPEC)可带来无疾病生存(DFS)优势。同样,Gueli-Alletti 等人证明了 MIS 方法在 IDS 中的可行性和安全性。此外,Petrillo 等人报告了在 MIS 后接受 HIPEC 的患者的药代动力学特征,其化疗浓度较高。因此,以下综述探讨了 MIS 和 HIPEC 联合应用的肿瘤学和临床安全性后果。根据系统评价和荟萃分析的首选报告项目(PRISMA)声明的建议,我们于 2022 年 4 月系统地检索了 PubMed 和 Scopus 数据库。包含肿瘤学和安全性结果数据的研究被纳入。我们在 PROSPERO 网站上注册了该综述,以进行荟萃分析,编号为 CRD42022329503。五项研究符合纳入标准。从三个不同的妇科肿瘤学转诊中心共纳入 42 名患者。系统综述强调复发率在 0%至 100%之间,3 年无铂生存介于 10%至 70%之间。最常用的 HIPEC 药物是顺铂,浓度在 75 至 100mg/m 之间,平均温度为 42°C,持续 60 至 90 分钟。仅报告了 1 例急性肾功能不全。由于缺乏专门针对 MIS 和开放手术联合 HIPEC 治疗上皮性卵巢癌的直接比较的临床试验,因此无法确定这两种技术之间的肿瘤学优势。然而,所显示的安全性概况非常令人放心。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f02/10055964/92d224d1353a/medicina-59-00421-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验